scholarly journals Systemic corticosteroids in coronavirus disease 2019 (COVID‐19)‐related smell dysfunction: an international view

2021 ◽  
Author(s):  
Caroline Huart ◽  
Carl M. Philpott ◽  
Aytug Altundag ◽  
Alexander W. Fjaeldstad ◽  
Johannes Frasnelli ◽  
...  
Keyword(s):  
Systemic Corticosteroids ◽  
International View

An International View of Mental Illness and Homelessness

1998 ◽  
Vol 43 (2) ◽  
pp. 147-148
Author(s):  
Victoria L. Banyard
Keyword(s):  
Mental Illness ◽  
International View

scholarly journals Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis

2021 ◽  
Vol 104 ◽  
pp. 671-676
Author(s):  
Todd C. Lee ◽  
Emily G. McDonald ◽  
Guillaume Butler-Laporte ◽  
Luke B. Harrison ◽  
Matthew P. Cheng ◽  
...  
Keyword(s):  
Systemic Corticosteroids

scholarly journals Tocilizumab and Systemic Corticosteroids in the Management of COVID-19 Patients:A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Hadeel Alkofide ◽  
Abdullah Almohaizeie ◽  
Sara Almuhaini ◽  
Bashayer Alotaibi ◽  
Khalid M. Alkharfy
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Systemic Corticosteroids

scholarly journals Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm

2021 ◽  
Vol 13 ◽  
pp. 175883592199298
Author(s):  
Orthi Shahzad ◽  
Nicola Thompson ◽  
Gerry Clare ◽  
Sarah Welsh ◽  
Erika Damato ◽  
...  
Keyword(s):  
Adverse Events ◽  
Checkpoint Inhibitors ◽  
Case Reports ◽  
Case Series ◽  
Simple Algorithm ◽  
Cancer Therapeutics ◽  
Management Algorithm ◽  
Ocular Symptoms ◽  
Systemic Corticosteroids ◽  
Permanent Loss

Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition and early intervention are essential because the degree of tissue damage may be disproportionate to the symptoms, and lack of appropriate treatment risks permanent loss of vision. International guidelines on managing ocular IrAEs provide limited advice only. Importantly, local interventions can be effective and may avoid the need for systemic corticosteroids, thereby permitting the continuation of CPIs. We present a single institution case series of eight affected patients managed by our multidisciplinary team. Consistent with previously published series and case reports, we identified anterior uveitis as the most common ocular IrAE associated with CPIs requiring intervention. Based on our experience, as well as published guidance, we generated a simple algorithm to assist clinicians efficiently manage patients developing ocular symptoms during treatment with CPIs. In addition, we make recommendations for optimising treatment of uveitis and address implications for ongoing CPI therapy.

Sign in / Sign up

Export Citation Format

Share Document